Clinical trials demonstrate the effectiveness of CAR T cells, specifically ciltacabtagene autoleucel, in treating myeloma. Response rates indicate that about one-third of individuals showed no detectable myeloma after five years of treatment, suggesting potential for a cure. The study includes some of the longest follow-up periods recorded for this therapy, highlighting its growing significance in cancer treatment. The use of CAR T cells, engineered to target cancer cells, represents an advancing frontier in clinical oncology.
The use of engineered immune cells called chimeric antigen receptor (CAR) T cells to treat certain types of cancer is gaining momentum in the clinic. The authors report impressive response rates: one-third of the treated individuals had no evidence of detectable myeloma after five years without further therapy.
The clinical trial data presents some of the longest follow-up periods assessing the effectiveness of CAR-T therapy called ciltacabtagene autoleucel (cilta-cel) to treat myeloma.
Collection
[
|
...
]